PPT-DTG + TAF/FTC vs DTG + TDF/FTC vs EFV/TDF/FTC

ADVANCE Design Primary endpoint Proportion of patients with HIV RNA lt 50 cmL at W48 ITTE snapshot analysis noninferiority of TFAFTC if lower margin CI for the difference 10 80 power. ENCORE. EFV vs RPV. ECHO-THRIVE. STAR. EFV vs ETR. SENSE. DOR vs EFV. DRIVE-AHEAD. Design. Objective. Non inferiority of EFV 400 mg at W48: % HIV RNA < 200 c/. mL. by modified intention to treat analysis (all randomised participants who received at least . Doravirine. /Lamivudine/TDF is Non-Inferior to . Efavirenz. /. Emtricitabine. /TDF in Treatment-Naïve Adults With HIV-1 Infection: Week 48 Results of the Phase 3 DRIVE-AHEAD Study. Kathleen E Squires. Massachusetts General Hospital. Boston, Massachusetts. State-of-the-ART in Antiretroviral Therapy: Optimal Initial Regimens in 2016. Washington, DC: August 23, 2016. Thanks to Alice Pau, Roger Bedimo and Marilyn Shi for assistance with slides. Estudio GS-US-311-1089 . Estudio GS-US-366-1216 . Estudio GS-US-366-1160 . . Diseño. Endpoints. Primario: proporción de pacientes . con C. V . < 50 c/mL a S48 (ITT, . snapshot. ) ; no inferioridad si el margen inferior de IC95% de dos colas para la diferencia = - 8%, poder 85%. C. Orrell , K. Kintu, J.A. Coombs, A. Amara, L. Myer, J. Kaboggoza, B. Simmons, L. Else, C. Heiberg, C. Waitt, S. Walimbwa , E.M. Hodel, A. Hill, S. Khoo , M. Lamorde, on behalf of the DolPHIN-1 Study Group Treating and Preventing HIV in 2019: Interactive Cases From the Clinic(ians) Michael S. Saag , MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham GS-US-292-0109 Study. GS-US-311-1089 Study. . Design. Endpoints. Primary: proportion of patients maintaining HIV RNA < 50 c/mL at W48 (ITT, snapshot) ; non-inferiority if lower margin of a two-sided 95% CI for the difference = -10%, > 95% power. introduction . of . DTG. Nandita Sugandhi. ICAP at Columbia University. No conflicts of interest to declare. Overview. Introducing . DTG in guidelines now. Programmatic Context. Eligible patient populations. Study 1249. Elvitegravir-Cobicistat-TAF-FTC in HIV/HBV Coinfection . Study 1249: . Design. Source: Gallant J, et al. . J. . Acquir. Immune . Defic. . Syndr. . 2016;73:294-8.. Baseline ART. (n = 72). Study GS-366-1216. Switch from TDF to TAF, each with RPV and FTC. Study GS-366-1216: Design. Source: . Orkin. C et al. Lancet HIV. 2017;4:e195-e204.. *. NOTE. :. of 632 participants randomized, 2 were never treated (630 individuals treated). GEMINI 1 and GEMINI 2: Week 48 Data. DTG + 3TC . versus . DTG + TDF-FTC as Initial ART. GEMINI 1 and 2: Background. Source: Cahn P, et al. Lancet. 2019;393:143-55.. Study Design: GEMINI 1 and 2. Background. and . Virologic. Outcomes . for Treatment-experienced . People Living with HIV Switching to MTR or STR ART since 2018 . Ben Chastek. 1. , Amy Anderson. 1. , Joshua Gruber. 2. , Sunil Majethia. 2. , Woodie Zachry. ACTG 5202. EFV versus ATV/r, both with ABC-3TC or TDF-FTC. ACTG 5202: Study Design. Source: . Daar. ES, et al. . Ann Intern Med. 2011;154:445-56. . EFV + ABC-3TC. (n = 465). ATV + RTV + ABC-3TC. (n = 463). Associate Dean for Global Health. University of Alabama at Birmingham. Birmingham, Alabama. Cases from the Clinic(. ians. ): . Case. -based Panel Discussion. AU Final: 02/21/17. New York, New York: February 24, 2017.